Inhibitor Therapeutics, Inc.

Equities

INTI

US45720M1053

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 07:59:50 16/05/2024 pm IST			5-day change	1st Jan Change
0.13 ^USD	+46.12%		+7.79%	+41.30%

29/03	Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	CI

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022

November 15, 2022 at 02:50 am IST

Inhibitor Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported net loss was USD 0.077692 million compared to USD 0.071051 million a year ago.
For the nine months, net loss was USD 0.254169 million compared to USD 0.265071 million a year ago.

Latest news about Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	30/03	CI
Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board	19/12	CI
Inhibitor Therapeutics, Inc. Announces the Use of Itraconazole to Treat Basal Cell Carcinoma Nevus Syndrome	19/12	CI
Inhibitor Therapeutics, Inc. Enters into an Exclusive, Worldwide Licensing Agreement with Johns Hopkins University	14/12	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11	CI
Inhibitor Therapeutics, Inc. Appoints Michelle Yanez as an Independent Director and a Member of the Audit Committee	18/23/18	CI
Inhibitor Therapeutics, Inc. Appoints Ronald E. Osman as Non-Independent Director on the Board	30/23/30	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI
Inhibitor Therapeutics, Inc. Announces Board Changes	01/23/01	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	15/22/15	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	13/22/13	CI
Inhibitor Therapeutics, Inc. Announces Retirement of Debra Peattie from the Board of Directors	04/22/04	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	13/22/13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	30/22/30	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	30/22/30	CI
Inhibitor Therapeutics, Inc. Executes A Letter Agreement with Mayne Pharma to Amend the Loan Agreement and the Facility	19/22/19	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/21/12	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	13/21/13	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	26/21/26	CI
Inhibitor Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	26/21/26	CI
Inhibitor Therapeutics, Inc. and Mayne Pharma Ventures Pty Ltd Enters Into Loan Agreement	18/20/18	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020	16/20/16	CI
Inhibitor Therapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2020	12/20/12	CI

Chart Inhibitor Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Inhibitor Therapeutics, Inc. is a pharmaceutical development company. The Company is focused on developing and commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders. Its primary focus is on the development of therapies initially for basal cell carcinoma (BCC), prostate and lung cancers in the United States utilizing itraconazole, a drug approved by the United States Food and Drug Administration (FDA) to treat fungal infections. The Company has developed intellectual property and know-how related to the treatment of cancer patients using itraconazole. The Company's intellectual property in the form of issued United States patents includes treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors, and treatment of lung cancer using hedgehog pathway inhibitors.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
INHIBITOR THERAPEUTICS, INC.	+41.30%	1.53Cr
VERTEX PHARMACEUTICALS INCORPORATED	+7.40%	11TCr
REGENERON PHARMACEUTICALS, INC.	+10.94%	11TCr
ARGENX SE	+0.32%	2.23TCr
BIONTECH SE	-12.08%	2.22TCr
GENMAB A/S	-6.03%	1.94TCr
WUXI APPTEC CO., LTD.	-37.85%	1.79TCr
BEIGENE, LTD.	-6.18%	1.72TCr
NEUROCRINE BIOSCIENCES, INC.	+6.82%	1.43TCr
SAREPTA THERAPEUTICS, INC.	+34.75%	1.25TCr

Bio Therapeutic Drugs